+207.9%
PDD vs GSK
+80.7%
+127.2%
-87.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.7% | -1.9% | +2.6% | +1.3% |
| 7D | -4.1% | -1.8% | -2.2% | -3.5% |
| 30D | -9.6% | -2.2% | -7.4% | -9.0% |
| 3M | -4.3% | -1.8% | -2.5% | -4.0% |
| 6M | -18.8% | -10.6% | -8.1% | -16.2% |
| YTD | -27.5% | +4.4% | -31.9% | -29.1% |
| 1Y | -33.6% | +30.4% | -64.0% | -40.1% |
| 3Y | -20.4% | +60.1% | -80.5% | -35.6% |
| 5Y | -19.6% | +46.8% | -66.4% | -32.9% |
| All | +207.9% | +80.7% | +127.2% | +144.9% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling